Low/Intermediate PCa Video Chat, June 23, 2025
Low/Intermediate PCa Video Chat, June 23, 2025
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostics.
WELCOME all to our newly recorded Low/Intermediate Prostate Cancer Group. To receive notice when new recordings are posted, either follow us on this YouTube Channel or sign up to our Blog via https://ancan.org/contact-us/ – check New Blog box.
- Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
- Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern https://ancan.org/veterans/
- You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/
- Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Pick: AI improvements may make biopsies unnecessary. (bj)
Topics Discussed
AI improvements with PI-RADS for MRIs and their potential to make biopsies unnecessary; new PCa diagnosis with a personal history of kidney cancer and family history of PCa; micro or nano ultrasound as an alternative to MRI for biopsy guidance (e.g., in cases where MRI is difficult or contraindicated); PROTON vs. CyberKnife: comparison of treatment modalities; Prostox genetic testing to predict genitourinary (GU) toxicity; thoughts and opinions about repeat biopsies and when they are appropriate; transitioning from Active Surveillance to Low/Intermediate PCa treatment; seeking insight into radiation treatment options; biomarkers to defer biopsy (e.g., ExoDx, My Prostate Score 2, EpiSwitch PSE); importance of expert pathology review and specific expert pathologists (e.g., Dr. Jonathan Epstein, Dr. Ming Zhou); philosophy of screening and testing at any age with informed decision-making (e.g., PSA testing for information); SBRT (Stereotactic Body Radiation Therapy) as a treatment type, including CyberKnife as a specific technology; use of Barigel or SpaceOAR to protect the rectum during radiation; boost to Dominant Intraprostatic Lesion (DIL) in radiation and challenges with prostate movement during treatment; genetic markers like HOXB13 and HSD3B1 in PCa diagnosis; Decipher genetic testing and arterial AI as helpful tools; and focal treatment for prostate cancer.
Chat Log
AnCan Barniskis Room
HOXB13
AnCan Barniskis Room
Scott Eggener, uro http://www.uchospitals.edu/physicians/scott-eggener.html
John A
HSD3B1 HOXB13
John A
ming.zhou@mt.sinai.org
John A
advanceduropathology.com
Stuart
Dr. Ming Zhou Mount Sinai Health System Department of Pathology, Box 1194 Annenberg Bldg. 15th FL 1468 Madison Ave New York, NY 10029 Email: Ming.zhou@mountsinai.org Telephone: (212)241-8881
AnCan Barniskis Room
Dr. Jonathan Epstein https://advanceduropathology.com/
karl b
kbatschke@gmail.com
karl b
No
AnCan Barniskis Room
Prostox seminar ….. https://ancan.org/event/special-presentation-what-if-you-could-predict-the-risk-of-radiation-effects-prostox-and-beyond/
AnCan Barniskis Room
Don’t see you.
karl b
Just found my genetic testing. Abnormal gene is HOXB13
AnCan Barniskis Room
Thought so – that’s a fairly common mutatiion for cancer that runs in families.
karl b
Thank you all! I have to log off.
AnCan Barniskis Room
Don’t think it means much for treatment. But imprtant for Dx. . Do you have sons, Karl?